Zeda will produce OIC’s implant designs, fortifying and accelerating its mission to provide accessible trauma implants to patients on a worldwide scale.
CartiHeal is the developer of Agili-C, a novel sports medicine technology for cartilage regeneration in the knee.
Orthopedic M&A is more active and has higher multiples than general medtech, but economic conditions will limit growth for now.
Vyrsa manufactures and supports a complete portfolio of FDA-cleared sacroiliac joint fusion devices.
TeDan produces surgical access systems with a specialty focus in spine, neuro, orthopedic and cardiothoracic surgery.
Agili-C is a novel sports medicine technology developed to treat cartilage regeneration in the knee.
Xtant acquired certain assets, including equipment and inventory, used in RTI’s synthetic bone graft business and assumed the lease for the nanOss production facility.
The merger will integrate Advanced Biologics’ proprietary products into Isto’s growing portfolio of allografts in their Influx line.
Lima’s solutions include digital innovation and patient-tailored hardware, developed to improve patient outcomes following joint replacement surgery.
The acquisition is intended to expand BSC’s portfolio to provide more treatment options for chronic low back pain.
Elutia announced the divestiture of the company’s orthobiologics business unit to Berkeley Biologics.
The transaction includes the sale of all cervical and lumbar fusion products, including the STALIF technology platform.
The addition of Conformis offers a scalable future of personalized orthopedic device solutions to restor3d’s offerings.
The combined company will provide a comprehensive offering of musculoskeletal procedural solutions and enabling technologies.
Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair and orthopedic indications.
The move combines complementary product portfolios across spine and interventional pain management, geographic footprints and customer bases.
Conformis entered into a definitive merger agreement under which restor3d will acquire all outstanding shares of common stock of Conformis.
Don't have an account? Register
Forgot your password? Reset
Register for a free account
As a guest member you get access to more articles and webinars every month.
We noticed you used your personal email account. Please enter your company website URL.
Already have an account? Login
We’ll send a recovery link to your email.
I already have an account! Login